The mechanism by which the chlorothiazide drugs produce hyperuricemia is not known, but the frequent and simultaneous reduction in renal clearance of uric acid suggests a tubular effect (1-3). Gutman, Yu and Sirota (4) have demonstrated a similar decrease in uric acid clearance after acetazolamidel therapy, and more extensive studies by Frascarelli, Lucidi and Cozzali (3) have not only confirmed this but have shown that levels of hyperuricemia induced by acetazolamide equal those produced by chlorothiazide 2 and hydrochlorothiazide.3 The present studies were designed to confirm these previously reported findings, and to determine whether the effects of these drugs were additive. Complete urinary uric acid excretions and clearances were also done to test the dependence of the hyperuricemia upon diminished output.
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The findings confirm those of Frascarelli and associates but differ in indicating a greater hyperuricemic activity for hydrochlorothiazide than for acetazolamide, and in demonstrating an additive effect when these drugs are used in combination. Still more significantly, these studies show that in low doses, hydrochlorothiazide increased the excretion of uric acid with an associated hyperuricemia.
METHODS
Normal, healthy medical students were used as the subj ects for this study. They were required to ingest low purine diets, starting 48 hours prior to the first day * Supported by research grants (E-2757-C2 and A-3692) from the National Institutes of Allergy and Infectious Diseases, and Arthritis and Metabolic Diseases; and The I. W. Held Memorial Fellowship Fund. t IL W. Held Fellow.
1 Diamox, Lederle (2-acetylamino-1,3,4-thiadiazole-5-sulfonamide). 2 Diuril, Merck (6-chloro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide). 3 Hydrodiuril, Merck (6-chloro-7-sulfamyl-3,4 dihydro-1,2,4 benzothiadiazine-1,1-dioxide).
of study, and their use of salicylates, vitamins and caffeine-containing beverages was curtailed. Fasting blood specimens were collected each morning at intervals of 24 hours; the plasma was separated and frozen until time for chemical analysis. For the duration of the study each subject collected his total output of urine in 24-hour aliquots, using 1-gallon plastic containers with toluene as a preservative. These specimens were analyzed daily, immediately after measurement of each total volume, except at weekends when the urine aliquots were diluted 1: 10 with distilled water and stored at 4°C. The purpose of these dilutions was to prevent precipitation of uric acid with its loss to chemical quantitation. 'Uric acid was measured according to Brown's modification of the urea cyanide calorimetric method, and creatinine content was determined by Phillip's modification of the alkaline picrate method (5) . Duplicate analyses were performed on all specimens, and when the creatinine content varied by more than 10 per cent from the mean (or if the subj ect reported inadvertent or accidental loss of significant degree), the specimen was eliminated from the study. As a precaution against the possibility that a drug chromagen might interfere with these calorimetric analyses, the uricase method of Praetorius and Poulsen (6) was used to check samples of blood and urine.
RESULTS
Plasmia studies. The following data refer only to a) the plasma uric acid levels just prior to and following medication, and b) the group of subjects with control uric acid levels falling below the usually accepted upper normal limit of 6.0 mg per 100 ml. The initial (control) specimen was taken after at least 48 hours of low purine diet and immediately preceding the administration of drug. The next three plasma uric acid values refer to specimens drawn 24, 48 and 72 hours after the control, during which intervals all subjects except those in the control group continued the medication. Table I lists the mean uric acid levels (calculated to two decimal places) and the range of the daily levels found in each of the four groups of subjects studied.
The control group consisted of 15 subjects Each of the 11 subjects in the fourth group received 50 mg hydrochlorothiazide and 500 mg acetazolamide (in divided doses at 9 a.m. and 5 p.m.) daily for 3 days. In this group the initial plasma uric acid values ranged from 3.4 to 5.4 mg per 100 ml (mean 4.77). After therapy the levels increased in all 11 subjects; the third and final readings extended from 4.8 to 8.1 mg per 100 ml (mean, 6.53).
In each of these four groups the uricase method of Praetorius and Poulsen was used to check the results of three of the subjects and to confirm the relative changes in plasma uric acid levels.
Statistical analysis of each of these groups (comparing the initial with the final plasma levels) by Wilcoxan's signed-rank test (7) shows that variations in plasma uric acid levels were insignificant in the control group, but significant with a probability of less than 0.01 for those medicated with acetazolamide and hvdrochlorothiazide separately and in combination.
By using the Wilcoxan-White two-sample rank test (7) to compare each of these groups with the others, no significant variation is found in the Plasma and urine studies. The hyperuricemia initial plasma levels of all four groups. How-induced by acetazolamide is associated with a deever, the elevated third-day plasma levels in the creased urinary excretion of uric acid. Table II acetazolamide, hydrochlorothiazide and combined-lists the data obtained from Subject R.H. Durdrug groups differ significantly from the corre-ing the 4-day control period his calculated renal sponding final levels in those receiving no drug, clearance of uric acid ranged from 10.7 to 12.0 ml with p values of less than 0.01. Comparison of per minute. Acetazolamide caused a relative hythe degree of change in plasma uric acid levels peruricemia and a diminished excretion of uric induced by acetazolamide and hydrochlorothiazide acid, with a marked decrease in the renal clearance shows the increased levels in the hydrochlorothia-(which fell to levels ranging from 5.8 to 9.0 ml zide group to be significant, with p equal to 0.05. per minute). In the recovery period after the drug Moreover, the hyperuricemia produced by com-was discontinued, no increased excretion of uric bined therapy is significantly greater than that of acid was found, as one would expect if the hypereach drug alone, with p less than 0.01. uricemia were purely the result of renal retention. t Hydrochlorothiazide, 50 mg daily in 2 divided doses for 7 days.
As in Table II .
DRUG-INDUCED HYPERURICEMIA
A similar study was done on a single subject; C.R. initially received 50 mg hydrochlorothiazide daily for 8 days, and 4 weeks later, 50 mg hydrochlorothiazide and 500 mg acetazolamide daily for 8 days (Table V) . Combined therapy produced the greater degree of hyperuricemia and the greater fall in the calculated renal clearance of uric acid but, during each procedure, the uric acid excretion under medication exceeded the control. The mean control uric acid excretions were 503 and 519 mg per 24 hours, while the mean excretions during drug therapy were 593 and 556 mg per 24 hours.
These results were confirmed in four addtional subjects, two of whom are reported here. W.Z. received 75 mg hydrochlorothiazide daily for 6 days, and J.M. received 50 mg hydrochlorothiazide daily for 7 days (Table VI) . In both cases the urinary excretions and plasma levels of uric acid rose, while the calculated renal clearances diminished slightly but returned to control levels before drugs were discontinued. Moreover, and still more significantly, this hyperuricosuria persisted even after medication was discontinued, and in both instances the renal clearance of uric acid rose to levels exceeding those of the initial control periods. The plasma and urine of two of these subjects were analyzed by the uricase method as well and the results confirmed.
DISCUSSION
Our data support previous observations (3, 4) that acetazolamide can induce hyperuricemia and decrease the renal excretion and clearance of uric acid. Confirmatory analysis of plasma and urine by the uricase method establishes that these changes and measurements truly represent uric acid. Also confirming this activity of acetazolamide is its ability to potentiate the hyperuricemia induced by hydrochlorothiazide.
These data support the concept that this effect of acetazolamide is renally mediated. However, the observation that small doses of hydrochlorothiazide produce an increased excretion of uric acid is not compatible with the concept of renal retention as the mechanism for the associated hyperuricemia. The dual properties of the chlorothiazide drugs in increasing as well as decreasing the excretion of uric acid have previously been noted and likened to the paradoxical actions of uricosuric agents such as acetylsalicylic acid and probenecid (2, 8) . Yu and Gutman feel that these drugs may exert either of two effects on the renal excretion of uric acid (9) : at low concentrations they supposedly reduce the tubular secretion and consequently the excretion and clearance of uric acid; at higher dosage they inhibit the tubular reabsorption and increase the excretion and clearance. However, our data show that the increased excretion of uric acid occurs at lower doses of hydrochlorothiazide and is accompanied by hyperuricemia and a slight decrease or no change in renal clearance. This pattern of events could be produced by either mobilization of urate from the miscible pool or a decrease in the nonrenal disposal of uric acid (10) , but neither of these mechanisms could account for the further increase in urinary uric acid excretion that occurred immediately after hydrochlorothiazide was discontinued.
An alternative explanation is that the drug increased the production of uric acid. Uricogenesis can be produced by drug therapy, as demonstrated by Krakoff and Balis, using ethylaminothiadiazole (EATDA) (11) .
The close chemical relationship of acetazolamide (2-acetylamino-1,3,4 thiadiazole-5-sulfonamide) and EATDA (2-ethylamino-1,3,4 thiadiazole) (see Figure 1) suggests a possible mechanism by which hydrochlorothiazide, in varying doses, can increase or decrease the urinary excretion of uric acid. Krakoff and Balis found that EATDA greatly enhanced the de novo synthesis of purine nucleotides and did not increase the yield of uric acid from nucleic acids. Actually, their data indicate a decreased yield of uric acid from nucleic acid. EATDA may have a dual effect on uric acid metabolism, at least one of which is shared with acetazolamide. If EATDA does decrease the degradation of nucleic acids, a loss of feedback inhibition by purine or purine nucleotide salvage mechanisms could result in greatly increased de novo synthesis of purine nucleotides (12) (13) (14) . Acetazolamide could have the same initial effect on nucleic acid degradation but could block the compensatory synthesis of purine nucleotides in a manner similar to the inhibition of bacterial nucleotide synthesis by the sulfonamide drugs (15) . Hydrochlorothiazide could act similarly, with low doses allowing, and higher doses inhibiting, the compensatory de novo synthesis of lurine nucleotides.
SUMMARY
The data presented support the concept that acetazolamide produces a relative hyperuricemia and a decreased renal excretion and clearance of uric acid. Although this hyperuricemia is not so great as that produced by hydrochlorothiazide, the two drugs together have an additive effect.
Hydrochlorothiazide, in low doses, produces a relative hyperuricemia with increased excretion of uric acid and without marked changes in its renal clearance.
The possibility is discussed that these drugs may exert an effect on uric acid through complex metalbolic pathways rather than a renal tubular one.
